Surrozen (NASDAQ:SRZN) Major Shareholder Purchases $15,628.78 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc bought 731 shares of the company’s stock in a transaction on Monday, February 2nd. The stock was bought at an average price of $21.38 per share, for a total transaction of $15,628.78. Following the completion of the purchase, the insider owned 639,507 shares of the company’s stock, valued at approximately $13,672,659.66. The trade was a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc purchased 4,355 shares of Surrozen stock. The stock was bought at an average cost of $21.94 per share, with a total value of $95,548.70.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The stock was purchased at an average price of $21.39 per share, for a total transaction of $91,356.69.

Surrozen Trading Down 10.1%

SRZN stock opened at $21.25 on Friday. Surrozen, Inc. has a 1-year low of $5.90 and a 1-year high of $25.47. The stock has a market cap of $182.11 million, a price-to-earnings ratio of -0.95 and a beta of 0.58. The company’s 50 day moving average is $20.81 and its 200 day moving average is $15.14.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%.The business had revenue of $0.98 million during the quarter. As a group, sell-side analysts forecast that Surrozen, Inc. will post -8.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. boosted its position in Surrozen by 50.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares during the last quarter. Citadel Advisors LLC increased its stake in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock worth $179,000 after acquiring an additional 3,424 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after acquiring an additional 5,702 shares during the period. Armistice Capital LLC acquired a new position in shares of Surrozen during the 2nd quarter valued at about $536,000. Finally, Woodline Partners LP acquired a new position in Surrozen in the 3rd quarter valued at about $621,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research note on Friday, November 28th. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.